Strata Critical Medical, Inc. (SRTA)
| Market Cap | 439.15M |
| Revenue (ttm) | 197.14M |
| Net Income (ttm) | 41.35M |
| Shares Out | 86.45M |
| EPS (ttm) | 0.50 |
| PE Ratio | 10.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 557,622 |
| Open | 4.90 |
| Previous Close | 4.95 |
| Day's Range | 4.87 - 5.09 |
| 52-Week Range | 2.57 - 6.02 |
| Beta | 2.11 |
| Analysts | Strong Buy |
| Price Target | 7.81 (+53.74%) |
| Earnings Date | May 6, 2026 |
About SRTA
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perf... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SRTA stock is "Strong Buy." The 12-month stock price target is $7.81, which is an increase of 53.74% from the latest price.
News
Strata Critical Medical Schedules First Quarter 2026 Earnings Conference Call
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the first quarter ended March 31, 2026 on Wednesday ...
Strata Critical Medical Transcript: 25th Annual Needham Virtual Healthcare Conference
The company leverages an asset-light, end-to-end logistics and clinical platform to drive growth in the fragmented organ transplant market, benefiting from regulatory changes and advances in perfusion technology. Its agnostic approach to devices, national footprint, and targeted acquisitions position it for continued above-market expansion.
Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual He...
Strata Critical Medical Earnings Call Transcript: Q4 2025
Q4 2025 saw 35% organic growth, record revenue, and margin expansion, driven by logistics and clinical integration. 2026 guidance was raised on strong volumes and new customer wins, with continued M&A and asset-light strategy supporting growth.
Strata Critical Medical Announces Fourth Quarter 2025 Results
Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic g...
Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday,...
Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution
$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and re...
Strata Critical Medical Hosts 2025 Investor Day; Provides 2026 and Medium-Term Financial Guidance
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company") is hosting its 2025 Investor Day today at the Nasdaq MarketSite in New York City. Th...
Strata Critical Medical Transcript: Investor Day 2025
Strata has transformed into a pure-play, end-to-end provider for organ transplant and cardiac care, leveraging an open-source, asset-light model with selective aircraft ownership and proprietary tech. Financial guidance targets organic EBITDA doubling by 2029, with significant upside from M&A, cross-selling, and regulatory tailwinds.
Strata Critical Medical Earnings Call Transcript: Q3 2025
Revenue grew 36.7% year-over-year to $49.3M in Q3 2025, with record segment-adjusted EBITDA and margin improvement. Raised 2025 revenue guidance to $185M–$195M, reaffirmed EBITDA outlook, and ended the quarter with no debt and $76M in cash.
Strata Critical Medical Announces Third Quarter 2025 Results
Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) millio...
Strata Critical Medical Announces Date for Third Quarter Ending September 30, 2025 Earnings Release Conference Call
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the third quarter ended September 30, 2025 on Monday,...
Strata Announces 2025 Investor Day
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), will hold an Investor D...
OrganOx metra® Receives FDA Approval for Operation During Air Transport, Expanding Access to Life-Saving Liver Perfusion Technology
OrganOx Ltd., the organ technology company tackling the world's toughest transplant challenges, announced that its metra® normothermic machine perfusion (NMP) device has received approval from the U.S...
Strata Acquires Keystone Perfusion, Creating Integrated Organ Recovery Platform, Diversifying into Other Medical Services
Keystone is expected to generate approximately $65 million of revenue and approximately $13 million of Adjusted EBITDA (1) in the full-year 2025, with revenue expected to grow more than 50% in 2025 ve...
Strata Critical Medical Transcript: Jefferies Mining and Industrials Conference 2025
Divesting the passenger business enables a focused push into the fast-growing medical logistics market, leveraging regulatory and technological shifts to expand services and improve margins. Strategic partnerships and an asset-light model drive competitive advantage and financial efficiency.
Strata Critical Medical to Present at the 2025 Jefferies Industrials Conference
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE) today announced that Will...
Blade Completes Sale of Passenger Business and Planned Name Change to Strata Critical Medical, Begins Trading Under Ticker Symbol SRTA
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), today announced the succ...
Blade Air Mobility Sets Timing for Name Change to Strata Critical Medical and Commencement of Trading Under the New Ticker Symbol “SRTA”
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), today confirmed that the previously announced change of its legal name to Strata Critical...
Strata Critical Medical Transcript: Oppenheimer 28th Annual Technology, Internet & Communications Conference
A major divestiture will refocus the business on medical logistics, leveraging a large, flexible aircraft network and expanding high-margin ancillary services. Regulatory and technological advances are driving market growth, with strong financial performance and high customer retention expected to continue.
Blade Air Mobility to Present at the Oppenheimer 28th Annual Technology, Internet & Communications Conference
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), a technology-powered air mobility platform, today announced that Will Heyburn, Chief Fina...
Strata Critical Medical Earnings Call Transcript: Q2 2025
Announced sale of the passenger business for up to $125M, transforming into a pure-play medical air mobility provider with strong Q2 medical revenue growth of 17.6% year-over-year. Medical segment now drives 60% of revenue and is positioned for further organic and M&A-driven expansion.
Blade Air Mobility Announces Second Quarter 2025 Results
Medical revenue increased 17.6% year-over-year in Q2 2025. Net loss improved by $7.6 million versus the prior year to $(3.7) million in Q2 2025; Adjusted EBITDA improved by $2.2 million versus the pri...
Blade announces sale of Passenger Division to Joby, Transitions to Pure-Play Medical Services and Logistics Business
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”) today announced an agreement to sell Blade's passenger division to Joby Aviation, Inc. (NY...
Blade Air Mobility Announces Date for Second Quarter Ending June 30, 2025 Earnings Release Conference Call
NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), will release financial results for the second quarter ended June 30, 2025 on Tuesday, Aug...